Comparison
Eloralintide vs. Maridebart Cafraglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
no data
Molecular weight
no data
no data
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Eloralintide
Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
2
1
of which in humans
1
1
Effects recorded
2
2
Open conflicts
0
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Eloralintide and Maridebart Cafraglutide?
- Eloralintide is classified as "Metabolic", while Maridebart Cafraglutide is classified as "Metabolic". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Eloralintide or Maridebart Cafraglutide?
- The highest available evidence level is "Human RCT" for Eloralintide and "Human RCT" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Eloralintide and Maridebart Cafraglutide in Germany and the United States?
- Germany: Eloralintide — Unapproved, Maridebart Cafraglutide — Unapproved. United States: Eloralintide — Unapproved, Maridebart Cafraglutide — Unapproved. These are factual summaries with source and review date on the individual pages.